Nanobiotix is up 4% on the Paris Bourse this Monday, after reporting new clinical results at the European Society of Oncology (ESMO) congress.

The findings of a Phase I study conducted in advanced pancreatic cancer showed a median survival of 23 months for patients receiving NBTXR3 injection in combination with radiotherapy, compared with 19 months with radiotherapy alone.

In another Phase I study, this time in head and neck cancer, patient survival was 43 months with NBTXR3 in addition to radiotherapy, compared with 18 months with radiotherapy alone.

NBTXR3 - the nanomedicine company's main project - is a hafnium nanoparticle compound that boosts the anti-tumor effect of radiotherapy by a factor of 9.

It is currently undergoing a dozen clinical trials, in partnership with institutions including Gustave Roussy and industrial groups such as Johnson & Johnson.

Copyright (c) 2023 CercleFinance.com. All rights reserved.